<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Rule 13d-102)
Information to be Included in Statements Filed Pursuant to
Rules 13d-1(b) and (c) and Amendments Thereto Filed Pursuant to 13d-2(b)
(Amendment No. 5)/1/
Interneuron Pharmaceuticals, Inc.
-------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.001 par value
- --------------------------------------------------------------------------------
(Title of Class of Securities)
460573 10 8
- --------------------------------------------------------------------------------
(CUSIP Number)
May 5, 1998
- --------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[_] Rule 13 d-1(b)
[_] Rule 13 d-1(c)
[X] Rule 13 d-1(d)
/1/ The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
- ----------------------- ---------------------
CUSIP NO. 460573 10 8 13G PAGE 2 OF 5 PAGES
- ----------------------- ---------------------
- ------------------------------------------------------------------------------
NAME OF REPORTING PERSON
1 S.S. or I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Lindsay Rowsenwald, M.D.
###-##-####
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
2 (a) [_]
(b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
4
United States
- ------------------------------------------------------------------------------
SOLE VOTING POWER
5
NUMBER OF
2,593,315
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 6
OWNED BY 0
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
7
REPORTING
2,593,315
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 8
0
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9
2,593,315
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
10
[X]
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
11
6.2%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
12
IN
- ------------------------------------------------------------------------------
SEC 174__ (6-__) *SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
Page 3 of 5
Item 1(a). Name of Issuer :
Interneuron Pharmaceuticals, Inc. (the "Issuer")
Item 1(b). Address of Issuer's Principal Executive Offices:
One Ledgemont Center
99 Hayden Avenue
Lexington, Massachusetts 02173
Item 2(a). Name of Person Filing:
Lindsay Rosenwald, M.D.
Item 2(b). Address of Principal Business Office or if none, Residence:
787 Seventh Avenue
New York, New York 10019
Item 2(c). Citizenship:
United States
Item 2(d). Title of Class of Securities:
Common Stock, $.001 par value ("Shares")
Item 2(e). CUSIP Number:
460573 10 8
Item 3. Not Applicable
<PAGE>
Page 4 of 5
Item 4. Ownership:
(a) As of December 31, 1998 Dr. Rosenwald beneficially owned
2,593,315 Shares.
Includes (i) 300,000 Shares which have been pledged in favor of a bank
to secure certain lease obligations of an associate of Dr. Rosenwald
and (ii) 80,834 Shares issuable upon exercise of options which are
exercisable within 60 days. Excludes (i) 109,166 Shares issuable upon
exercise of options which, as of December 31, 1998, were not
exercisable within 60 days, (ii) 658,481 Shares owned by Dr.
Rosenwald's wife, as to which Shares Dr. Rosenwald disclaims
beneficial ownership and (iii) 37,800 Shares owned by two limited
partnerships, the limited partners of which include Dr. Rosenwald's
wife and children, as to which Shares Dr. Rosenwald disclaims
beneficial ownership.
(b) Percent of Class: 6.2%.
(c) (i) Number of shares as to which such person has sole power
to vote or direct the vote: 2,593,315.
(ii)-(iv) Reference is made to items 6-8 of the cover page.
Item 5. Ownership of Five Percent or Less of a Class
Not Applicable
Item 6. Ownership of More than Five Percent on Behalf of Another Person
Not Applicable
Item 7. Identification and Classification of Subsidiary Which Acquired the
Securities
Not Applicable
Item 8. Identification and Classification of Members of the Group
Not Applicable
<PAGE>
Page 5 of 5
Item 9. Notice of Dissolution of Group
Not Applicable
Item 10. Certification
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
February 10, 1999
--------------------------
Date
/s/Lindsay Rosenwald, M.D.
--------------------------
Signature
Lindsay Rosenwald, M.D.
--------------------------
Name/Title
